<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134380</url>
  </required_header>
  <id_info>
    <org_study_id>GIANT200905-04</org_study_id>
    <nct_id>NCT01134380</nct_id>
  </id_info>
  <brief_title>Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment</brief_title>
  <acronym>GIANT</acronym>
  <official_title>Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allies in Cardiovascular Trials Initiatives and Organized</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of GIANT Study is to evaluate the clinical impact of genetic resistance to
      thienopyridine profile determination (CYP2C19 gene) and the clinical impact of compliance to
      an adjusted thienopyridine treatment on STEMI patients treated by primary PCI within the 24
      hours following the first chest pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the STEMI patients treated by primary PCI (with stent implantation) within the 24 hours
      following the first chest pain can be included in the GIANT study. After the PCI, they'll
      receive DAT (Aspirin + Clopidogrel/Prasugrel).

      Patients will then be genotyped to determine if they carry one of the CYP2C19 gene variants
      making them resistant or hyper responder to clopidogrel. The genetic profile of the patients
      will be communicated to the physician who took care of them so that he can (or not) adjust
      the thienopyridine treatment (increase of the clopidogrel dosage, switch to prasugrel or
      switch to clopidogrel). A treatment will be prescribed for 12 months as according to the
      European guidelines.

      One year after the PCI, the patients will have to be available for a follow up visit. They'll
      be submitted to a VERIFY NOW P2Y12 protocol to determine whether they were compliant to their
      thienopyridine treatment. A clinical follow up will be also performed to evaluate the
      cardiovascular events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>statistical difference in Death, MI and stent thrombosis between genetically resistant patients (*2 genotype) with adapted treatment and non resistant patients (*1 genotype)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in MACCE between responder + compliant patients vs responders + non compliant patients vs non responder patients.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Genetic Resistance to Clopidogrel</condition>
  <condition>Compliance to Thienopyridine Treatment</condition>
  <arm_group>
    <arm_group_label>[*1] Genotype - Good responders to Clopidogrel</arm_group_label>
    <description>This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[*2] genotype with adapted thienopyridine treatment</arm_group_label>
    <description>This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA Samples from saliva to observe CYP2C19 genetic variants
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        STEMI patients treated within the first 24 hours following the first chest pain by Primary
        PCI (with stent implantation)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI patient treated within the first 24 hours with primary PCI (with stent
             implantation)

          -  Age superior or equal to 18 years old

          -  Informed consent signed

          -  Patient volunteer to be submitted to the 1 year visit follow up and to the clinical
             exams during this visit

          -  Patient benefiting from French social health system

        Exclusion Criteria:

          -  NONSTEMI patient with high troponin

          -  STEMI patient treated after the first 24 hours

          -  Stable / unstable angina or silent ischemia

          -  Cardiogenic shock

          -  Oral anticoagulation (Vitamin K Antagonists)

          -  Contraindication for PCI

          -  Age inferior to 18 years old

          -  Life expectancy inferior to 1 year

          -  Participation in another clinical trial

          -  No signed informed consent

          -  Patient not available for the 1 year visit follow up

          -  Pregnant women

          -  Known allergy to media contrast that can not be controlled by an adapted treatment

          -  Known allergy to cobalt chromium alloy

          -  Left ventricular ejection fraction lower than 30%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Chevalier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Privé Jacques Cartier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Montalescot</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loïc Belle</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de la région Annecienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de la Région Annecienne</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Albert Schweitzer</name>
      <address>
        <city>Colmar</city>
        <zip>68003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Haguenau</name>
      <address>
        <city>Haguenau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Joseph et Saint Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bon Secours</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Rene Dubos</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de Villeneuve</name>
      <address>
        <city>Villeneuve Saint Georges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <name_title>Virginie COLIN</name_title>
    <organization>Biotronik France</organization>
  </responsible_party>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Dual antiplatelet therapy</keyword>
  <keyword>clopidogrel/prasugrel</keyword>
  <keyword>genotyping</keyword>
  <keyword>stent</keyword>
  <keyword>compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

